Please login to the form below

Not currently logged in


This page shows the latest Pomalyst news and features for those working in and with pharma, biotech and healthcare.

Celgene’s triple multiple myeloma therapy clears phase III trial

Celgene’s triple multiple myeloma therapy clears phase III trial

Its presence in the field is showing no signs of wavering either, following new data from a pivotal phase III trial of Pomalyst whose results are looking good for Celgene. ... Pomalyst (pomalidomide) - Celgene’s second biggest earner - brought in

Latest news

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...